Argosy Investors Q4 Moves: New Positions and Exits
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy NVO?
Source: seekingalpha
- New Investment Position: Argosy Investors acquired shares in Floor & Décor (FND) during Q4, noting that the company's current EBIT margins are approximately 30% below pre-COVID long-term levels, and anticipates margins will scale towards the low-to-mid-teens as the store base expands, enhancing profitability and market competitiveness.
- Exit from Unfavorable Investment: The fund sold its position in Novo Nordisk (NVO) after a brief holding period due to findings from further due diligence indicating a disadvantageous competitive situation, demonstrating caution and flexibility in investment decisions.
- Increased Confidence in Holdings: Argosy also strengthened its position in Endava (DAVA) during Q4, believing that its share price performance is largely company-specific and that there is a significant chance of mean reversion if DAVA can demonstrate inflecting organic revenue growth, indicating confidence in its future growth potential.
- Market Dynamics Insight: In analyzing market dynamics, Argosy is attentive to Novo Nordisk's competitive landscape and market pressures, particularly in light of positive mid-stage trial results for its obesity drug in China, showcasing keen insights into industry trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.750
Low
42.00
Averages
54.67
High
70.00
Current: 36.750
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Novo Nordisk's New Drug Approval May Aid Market Comeback
- New Drug Approval: On March 19, Novo Nordisk announced FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in clinical trials, surpassing the original's 15.5%, potentially aiding the company's competitive position in the weight-loss market.
- Increased Competitive Pressure: Although HD Wegovy outperforms the original formulation, it still falls short of Eli Lilly's Zepbound, which achieved a 20.2% weight loss in head-to-head studies, highlighting the challenges Novo Nordisk faces in regaining market leadership.
- Multiple Indication Advantage: Zepbound's approval for treating obstructive sleep apnea in overweight patients provides it with an additional edge, further complicating Novo Nordisk's efforts to reclaim its top position in the market.
- Future Potential: Novo Nordisk has promising candidates like Amycretin and UBT251 in its pipeline, and positive clinical trial results could boost its stock price, although immediate recovery of market leadership appears unlikely.
See More
Novo Nordisk Launches New Version of Wegovy
- New Drug Approval: On March 19, Novo Nordisk received FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in a 72-week clinical trial, significantly outperforming the original version's 15.5%, indicating potential in the weight-loss market.
- Competitive Market Pressure: Despite the improved efficacy of HD Wegovy, it still lags behind Eli Lilly's Zepbound, which achieved a 20.2% weight loss in a similar study, maintaining competitive pressure on Novo Nordisk in the obesity treatment sector.
- Future R&D Prospects: Novo Nordisk is advancing its weight-loss drug pipeline, with potential clinical trial results for candidates like Amycretin and UBT251 expected in the next two years, which could enhance the company's competitive position in the market.
- Attractive Stock Valuation: Although facing challenges, Novo Nordisk's stock is currently trading at a forward P/E of 10.9, below the healthcare sector average of 17.1, indicating its attractiveness for long-term investors and potential for stable returns.
See More
Novo Nordisk's Wegovy Receives Major Recommendation
- Cardiovascular Risk Management: Novo Nordisk's Wegovy has been recommended by the National Institute for Health and Care Excellence for use in adults at high cardiovascular risk, marking it as the first GLP-1 medicine approved specifically for reducing future cardiovascular events, which is expected to significantly enhance patient health management.
- Potential Beneficiary Population: This guidance is anticipated to make approximately 1.2 million people eligible for Wegovy treatment through the National Health Service, thereby expanding the drug's accessibility and potentially positively impacting Novo Nordisk's market share.
- Clinical Data Support: Clinical trial data indicates that semaglutide, the active ingredient in Wegovy, can reduce the risk of major cardiovascular events by 20% when used alongside existing heart medications, further validating its importance in cardiovascular disease management.
- Market Reaction: Although Novo Nordisk's stock fell by 0.08% during trading on the New York Stock Exchange, this recommendation may bolster investor confidence in the company over the long term, potentially driving a rebound in stock price.
See More
Eli Lilly's Weight Loss Drug Approved by FDA
- Stock Surge: Eli Lilly (LLY) shares rose 5% following the FDA's approval of its oral weight loss drug orforglipron, reflecting market optimism about the drug's potential sales and likely boosting future revenue growth for the company.
- Drug Approval Context: The drug is approved for use in conjunction with a reduced-calorie diet and increased physical activity to help adults with obesity or overweight maintain long-term weight loss, highlighting its significance in treating weight-related health issues.
- Accelerated Review Process: The FDA granted approval 294 days ahead of the deadline under the National Priority Voucher pilot program, indicating the agency's prioritization of weight loss medications, which may set a precedent for the approval of similar drugs.
- Market Potential: With the rising prevalence of obesity, the launch of orforglipron not only addresses a critical market need but also positions Eli Lilly to capture a larger share in the competitive weight loss drug market, enhancing its market standing.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Novo Nordisk's New Drug Approval May Aid Market Comeback
- New Drug Approval: On March 19, Novo Nordisk announced FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in clinical trials, surpassing the original's 15.5%, potentially aiding the company's competitive position in the weight-loss market.
- Increased Competitive Pressure: Although HD Wegovy outperforms the original formulation, it still falls short of Eli Lilly's Zepbound, which achieved a 20.2% weight loss in head-to-head studies, highlighting the challenges Novo Nordisk faces in regaining market leadership.
- Multiple Indication Advantage: Zepbound's approval for treating obstructive sleep apnea in overweight patients provides it with an additional edge, further complicating Novo Nordisk's efforts to reclaim its top position in the market.
- Future Potential: Novo Nordisk has promising candidates like Amycretin and UBT251 in its pipeline, and positive clinical trial results could boost its stock price, although immediate recovery of market leadership appears unlikely.
See More
Novo Nordisk Launches New Version of Wegovy
- New Drug Approval: On March 19, Novo Nordisk received FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in a 72-week clinical trial, significantly outperforming the original version's 15.5%, indicating potential in the weight-loss market.
- Competitive Market Pressure: Despite the improved efficacy of HD Wegovy, it still lags behind Eli Lilly's Zepbound, which achieved a 20.2% weight loss in a similar study, maintaining competitive pressure on Novo Nordisk in the obesity treatment sector.
- Future R&D Prospects: Novo Nordisk is advancing its weight-loss drug pipeline, with potential clinical trial results for candidates like Amycretin and UBT251 expected in the next two years, which could enhance the company's competitive position in the market.
- Attractive Stock Valuation: Although facing challenges, Novo Nordisk's stock is currently trading at a forward P/E of 10.9, below the healthcare sector average of 17.1, indicating its attractiveness for long-term investors and potential for stable returns.
See More
Novo Nordisk's Wegovy Receives Major Recommendation
- Cardiovascular Risk Management: Novo Nordisk's Wegovy has been recommended by the National Institute for Health and Care Excellence for use in adults at high cardiovascular risk, marking it as the first GLP-1 medicine approved specifically for reducing future cardiovascular events, which is expected to significantly enhance patient health management.
- Potential Beneficiary Population: This guidance is anticipated to make approximately 1.2 million people eligible for Wegovy treatment through the National Health Service, thereby expanding the drug's accessibility and potentially positively impacting Novo Nordisk's market share.
- Clinical Data Support: Clinical trial data indicates that semaglutide, the active ingredient in Wegovy, can reduce the risk of major cardiovascular events by 20% when used alongside existing heart medications, further validating its importance in cardiovascular disease management.
- Market Reaction: Although Novo Nordisk's stock fell by 0.08% during trading on the New York Stock Exchange, this recommendation may bolster investor confidence in the company over the long term, potentially driving a rebound in stock price.
See More
Eli Lilly's Weight Loss Drug Approved by FDA
- Stock Surge: Eli Lilly (LLY) shares rose 5% following the FDA's approval of its oral weight loss drug orforglipron, reflecting market optimism about the drug's potential sales and likely boosting future revenue growth for the company.
- Drug Approval Context: The drug is approved for use in conjunction with a reduced-calorie diet and increased physical activity to help adults with obesity or overweight maintain long-term weight loss, highlighting its significance in treating weight-related health issues.
- Accelerated Review Process: The FDA granted approval 294 days ahead of the deadline under the National Priority Voucher pilot program, indicating the agency's prioritization of weight loss medications, which may set a precedent for the approval of similar drugs.
- Market Potential: With the rising prevalence of obesity, the launch of orforglipron not only addresses a critical market need but also positions Eli Lilly to capture a larger share in the competitive weight loss drug market, enhancing its market standing.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
